Selectivity and activation of dopamine D3R from molecular dynamics

Journal of Molecular Modeling

Volumn 18, Issue 12, 2012, Pages 5051-5063

  Feng, Zhiwei ^a   Hou, Tingjun ^a   Li, Youyong ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Conformational changes; D3 receptor; Mechanism of selectivity and activation; Molecular dynamics

Indexed keywords

APOMORPHINE; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; LIGAND;

ARTICLE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; PRIORITY JOURNAL; THREE DIMENSIONAL IMAGING;

BINDING SITES; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HUMANS; HYDROGEN BONDING; LIGANDS; LIPID BILAYERS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, DOPAMINE D3; STRUCTURAL HOMOLOGY, PROTEIN; THERMODYNAMICS;

RUMEX;

EID: 84870595334     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-012-1509-x     Document Type: Article

References (66)

1. Chien EYT, Liu W, Zhao QA, Katritch V, Han GW, Hanson MA, Shi L, Newman AH, Javitch JA, Cherezov V, Stevens RC (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330:1091-1095.
2. Ortore G, Tuccinardi T, Bertini S, Martinelli A (2006) A theoretical study to investigate D2DAR/D4DAR selectivity: receptor modeling and molecular docking of dopaminergic ligands. J Med Chem 49:1397-1407.
3. Heidbreder CA, Gardner EL, Xi ZX, Thanos PK, Mugnaini M, Hagan JJ, Ashby CR (2005) The role of central dopamine D-3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Rev 49:77-105.
4. Ji M, Chen JY, Ding K, Wu XH, Varady J, Levant B, Wang SM (2005) Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopainine receptor 3 (D-3) ligands. Bioorg Med Chem Lett 15:1701-1705.
5. Joyce JN, Milian MJ (2005) Dopamine D-3 receptor antagonists as therapeutic agents. Drug Discov Today 10:917-925.
6. Newman AH, Grundt P, Nader MA (2005) Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem 48:3663-3679.
7. Sasse BC, Mach UR, Leppaenen J, Calmels T, Stark H (2007) Hybrid approach for the design of highly affine and selective dopamine D-3 receptor ligands using privileged scaffolds of biogenic amine GPCR ligands. Bioorg Med Chem 15:7258-7273.
8. Feng Z, Hou T, Li Y (2012) Studies on the interactions between β2 adrenergic receptor and Gs protein by molecular dynamics simulations. J Chem Inf Model 52:1005-1014.
9. Li Y, Hou T, Goddard I (2010) Computational modeling of structure-function of G protein-coupled receptors with applications for drug design. Curr Med Chem 17:1167-1180.
10. Goddard WA III, Kim SK, Li Y, Trzaskowski B, Griffith AR, Abrol R (2010) Predicted 3D structures for adenosine receptors bound to ligands: comparison to the crystal structure. J Struct Biol 170:10-20.
11. Hall DA, Strange PG (1999) Comparison of the ability of dopamine receptor agonists to inhibit forskolin-stimulated adenosine 3′ 5′-cyclic monophosphate (cAMP) accumulation via D-2 L (long isoform) and D-3 receptors expressed in Chinese hamster ovary (CHO) cells. Biochem Pharmacol 58:285-289.
12. Newman AH, Grundt P, Cyriac G, Deschamps JR, Taylor M, Kumar R, Ho D, Luedtke RR (2009) N-(4-(4-(2, 3-Dichloro- or 2-methoxyphenyl)piperazin-1-yl) butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. J Med Chem 52:2559-2570.
13. Cho DI, Zheng M, Kim KM (2010) current perspectives on the selective regulation of dopamine D-2 and D-3 receptors. Arch Pharm Res 33:1521-1538.
14. Ortega R, Ravina E, Masaguer CF, Areias F, Brea J, Loza MI, Lopez L, Selent J, Pastor M, Sanz F (2009) Synthesis, binding affinity and SAR of new benzolactam derivatives as dopamine D-3 receptor ligands. Bioorg Med Chem Lett 19:1773-1778.
15. Sokoloff P, Giros B, MartresMP, BouthenetML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146-151.
16. Boeckler F, Ohnmacht U, Lehmann T, Utz W, Hubner H, Gmeiner P (2005) CoMFA and CoMSIA investigations revealing novel insights into the binding modes of dopamine D3 receptor agonists. J Med Chem 48:2493-2508.
17. Zhang A, Neumeyer JL, Baldessarini RJ (2007) Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders. Chem Rev 107:274-302.
18. Boeckler F, Lanig H, Gmeiner P (2005) Modeling the similarity and divergence of dopamine D-2-like receptors and identification of validated ligand-receptor complexes. J Med Chem 48:694-709.
19. Livingstone CD, Strange PG, Naylor LH (1992) Molecular modelling of D2-like dopamine receptors. Biochem J 287:277-282.
20. Salama I, Hocke C, UtzW, Prante O, Boeckler F, Hubner H, Kuwert T, Gmeiner P (2007) Structure - selectivity investigations of D-2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D-3 selective PET radioligands. J Med Chem 50:489-500.
21. Zald DH, Woodward ND, Cowan RL, Riccardi P, Ansari MS, Baldwin RM, Cowan RL, Smith CE, Hakyemez H, Li R, Kessler RM (2010) The interrelationship of dopamine D2-like receptor availability in striatal and extrastriatal brain regions in healthy humans: A principal component analysis of [F-18]fallypride binding. NeuroImage 51:53-62.
22. Aujla H, Beninger RJ (2005) The dopamine D-3 receptorpreferring partial agonist BP 897 dose-dependently attenuates the expression of amphetamine-conditioned place preference in rats. Behav Pharmacol 16:181-186.
23. Beardsley PM, Sokoloff P, Balster RL, Schwartz JC (2001) The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not selfadministered. Behav Pharmacol 12:1-11.
24. Garcia-Ladona FJ, Cox BF (2003) BP 897, a selective dopamine D-3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction. CNS Drug Rev 9:141-158.
25. Wicke K, Garcia-Ladona J (2001) The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors. Eur J Pharmacol 424:85-90.
26. Wood MD, Boyfield I, Nash DJ, Jewitt FR, Avenell KY, Riley GJ (2000) Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor. Eur J Pharmacol 407:47-51.
27. Clement P, Pozzato C, Heidbreder C, Denys P, Giuliano F, Melotto S (2009) Sb-277011, a selective dopamine D3 receptor antagonist, delays ejaculation in conscious and anesthetized rats. Eur Urol Suppl 8:365-365.
28. Dravolina OA, Shekunova EV, Zvartau EE, van Gaalen MM, Drescher KU, Schoemaker H, Gross G, Bespalov AY (2007) Effects of the selective dopamine D3 receptor antagonist SB- 277011 on cue- and nicotine-induced relapse to nicotine-seeking behavior. Behav Pharmacol 18:S87-S87.
29. Gilbert JG, Newman AH, Gardner EL, Ashby CR, Heidbreder CA, Pak AC, Peng XQ, Xi ZX (2005) Acute administration of SB- 277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: Role of dopamine D-3 receptors. Synapse 57:17-28.
30. Khaled MATM, Araki KF, Li B, Coen KM, Marinelli PW, Varga J, Gaal J, Le Foll B (2010) The selective dopamine D-3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking. Int J Neuropsychoph 13:181-190.
31. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, Hadley MS, Hunter AJ, Jeffrey P, Jewitt F, Johnson CN, Jones DNC, Medhurst AD, Middlemiss DN, Nash DJ, Riley GJ, Routledge C, Stemp G, Thewlis KM, Trail B, Vong AKK, Hagan JJ (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D-3 receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294:1154-1165.
32. Spiller K, Xi ZX, Peng XQ, Newman AH, Ashby CR, Heidbreder C, Gaal J, Gardner EL (2008) The selective dopamine D-3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D-3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats. Psychopharmacology 196:533-542.
33. Thanos PK, Katana JM, Ashby CR, Michaelides M, Gardner EL, Heidbreder CA, Volkow ND (2005) The selective dopamine D3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats. Pharmacol Biochem Be 81:190-197.
34. Thanos PK, Michaelides M, Ho CW, Wang GJ, Newman AH, Heidbreder CA, Ashby CR, Gardner EL, Volkow ND (2008) The effects of two highly selective dopamine D-3 receptor antagonists (SB-277011A and NGB-2904) on food selfadministration in a rodent model of obesity. Pharmacol Biochem Be 89:499-507.
35. Martelle JL, Claytor R, Ross JT, Reboussin BA, Newman AH, Nader MA (2007) Effects of two novel D-3-selective compounds, NGB 2904 [N-(4-(4-(2, 3-dichlorophenyl)piperazin-1- yl)butyl)-9 H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4- (2, 3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 321:573- 582.
36. Xi ZX, Gardner EL (2007) Pharmacological actions of NGB 2904, a selective dopamine D-3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev 13:240-259.
37. Xi ZX, Newman AH, Gilbert JG, Pak AC, Peng XQ, Ashby CR, Gitajn L, Gardner EL (2006) The novel dopamine D-3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 31:1393-1405.
38. Stefan L, Harald H, Nuska T, Gmeiner P (2011) Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates. Trends Pharmacol Sci 32:148-157.
39. Silvano E, Millan MJ, la Cour CM, Han Y, Duan LH, Griffin SA, Luedtke RR, Aloisi G, Rossi M, Zazzeroni F, Javitch JA, Maggio R (2010) The tetrahydroisoquinoline derivative SB269, 652 Is an allosteric antagonist at dopamine D-3 and D-2 receptors. Mol Pharmacol 78:925-934.
40. Taylor S, Riley G, Hunter A, Stemp G, Routledge C, Hagna JCR (1999) SB269, 652 is a selective D3 receptor antagonist in vitro and in vivo. J Eur College Neuropsychopharmacol 9:S266.
41. Studio D (2007) version 2.5. Accelrys Inc.: San Diego, CA.
42. Wiederstein M, Sippl MJ (2007) ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res 35:W407-W410.
43. Laskowski RA, Rullmann JAC, MacArthur MW, Kaptein R, Thornton JM (1996) AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR 8:477-486.
44. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25:1605-1612.
45. Brooks BR, Bruccoleri RE, Olafson BD (1983) CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 4:187-217.
46. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79:926.
47. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14:33-38.
48. Li Y, Hou T (2010) Computational simulation of drug delivery at molecular level. Curr Med Chem 17:4482-4491.
49. Kim SK, Li Y, Abrol R, Heo J, Goddard WA III (2011) Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors. J Chem Inf Model 51:420-433.
50. Li Y, Zhu F, Vaidehi N, Goddard WA III, Sheinerman F, Reiling S, Morize I, Mu L, Harris K, Ardati A (2007) Prediction of the 3D structure and dynamics of human DP G-protein coupled receptor bound to an agonist and an antagonist. J Am Chem Soc 129:10720-10731.
51. Kim SK, Li Y, Park C, Abrol R, Goddard WA III (2010) Prediction of the three-dimensional structure for the rat urotensin ii receptor, and comparison of the antagonist binding sites and binding selectivity between human and rat receptors from atomistic simulations. Chem Med Chem 5:1594-1608.
52. Kalé L, Skeel R, Bhandarkar M, Brunner R, Gursoy A, Krawetz N, Phillips J, Shinozaki A, Varadarajan K, Schulten K (1999) NAMD2: greater scalability for parallel molecular dynamics* 1. J Comput Phys 151:283-312.
53. MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczera K, Lau FTK, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher WE, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiorkiewicz-Kuczera J, Yin D, Karplus M (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102:3586-3616.
54. Feller SE, MacKerell AD (2000) An improved empirical potential energy function for molecular simulations of phospholipids. J Phys Chem B 104:7510-7515.
55. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG (1995) A smooth particle mesh Ewald method. J Chem Phys 103:8577-8593.
56. Plesnar E, Subczynski WK, Pasenkiewicz-Gierula M (2012) Saturation with cholesterol increases vertical order and smoothes the surface of the phosphatidylcholine bilayer: a molecular simulation study. BBA-Biomembranes 1818:520-529.
57. Kalani MYS, Vaidehi N, Hall SE, Trabanino RJ, Freddolino PL, Kalani MA, Floriano WB, Kam VWT, Goddard WA (2004) The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. Prog Natl Acad Sci USA 101:3815-3820.
58. Zhang P, Cyriac G, Kopajtic T, Zhao YF, Javitch JA, Katz JL, Newman AH (2010) structure-ACTIVITY relationships for a novel series of citalopram (1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)- 1, 3-dihydroisobenzofuran-5- carbonitrile) analogues at monoamine transporters. J Med Chem 53:6112-6121.
59. Soriano-Ursúa MA, Ocampo-López JO, Ocampo-Mendoza K, Trujillo-Ferrara JG, Correa-Basurto J (2011) Theoretical study of 3-D molecular similarity and ligand binding modes of orthologous human and rat D2 dopamine receptors. Comput Biol Med 41:537- 545.
60. Andujar S, Tosso R, Suvire FD, Angelina EL, Peruchena N, Cabedo N, Cortes D, Enriz RD (2012) Searching the "biologically relevant" conformation of dopamine, a computational approach. J Chem Inf Model 52:99-112.
61. Zhao YX, Lu XF, Yang CY, Huang ZM, Fu W, Hou TJ, Zhang JA (2010) Computational modeling toward understanding agonist binding on dopamine 3. J Chem Inf Model 50:1633-1643.
62. Lebon G, Warne T, Edwards PC, Bennett K, Langmead CJ, Leslie AG, Tate CG (2011) Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474:521-525.
63. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree BT, Rosenbaum DM, Thian FS, Kobilka TS, Schnapp A, Konetzki I, Sunahara RK, Gellman SH, Pautsch A, Steyaert J, Weis WI, Kobilka BK (2011) Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 469:175-180.
64. Standfuss J, Edwards PC, Antona AD, Fransen M, Xie G, Oprian DD, Schertler GFX (2011) The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature 471:656-660.
65. Vignir I, Thomas B, Tommy S, Jørgensen FS, Isberg DEV (2011) G Protein- and agonist-bound serotonin 5-ht2a receptor model activated by steered molecular dynamics simulations. J Chem Inf Model 51:315-325.
66. Xu F, Wu H, Katritch V, Han G, Jacobson K, Gao Z, Cherezov V, Stevens R (2011) Structure of an agonist-bound human a2a adenosine receptor. Science 332:322-327.